SHR0302 (ivarmacitinib) is highly selective for JAK 1 and the first JAK inhibitor to be originally developed and now tested in a phase 3 RA clinical trial exclusively in China.
After 24 weeks of daily treatment, the primary endpoint of an ACR20 response was met by 40.4% of those who had been given placebo, 70.4% who had received a 4-mg dose, and 75.1% given an 8-mg dose. At the same time point, ACR50 responses were a respective 15.4%, 46.0%, and 57.1%, and ACR70 responses were 6.9%, 22.2%, and 31.7%. All analyses comparing SHR0302 vs placebo were highly significant .
Infection-related treatment-emergent adverse effects occurred slightly more often in the SHR0302-treated groups than in the placebo group . There was a single case of serious infection that required treatment in the SHR0302 8 mg–treated group but no cases of systemic opportunistic infection. As for malignancy, there was a single, newly diagnosed case in the SHR0302 4 mg group in the first part of the trial and two cases, both in the SHR0302 4 mg group, during the extension phase.
McInnes added,"It's really unclear whether the solution is going to be greater selectivity and potency, or whether we need to think really about selecting the right patients for a JAK inhibitor."
RA - Rheumatoid Arthritis Rheumatoid Arthritis (RA) Jak/Stat Jak-Stat Signaling Pathway Jak-Stat Cytokine Receptors Thromboembolism Disease-Modifying Antirheumatic Drugs Dmards DMARD Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Clinical Research Clinical Trials Clinical Studies Pre-Clinical Trial Double-Blind Study Double-Blind Studies
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Topical JAK inhibitor Effective for AD in Young Kids Up to 52 WeeksNo treatment-related interruptions, discontinuations, or serious adverse events were observed with ruxolitinib cream in children aged 2-11 years.
Read more »
New Crunchyroll Anime Proves the Limits of One Beloved Shonen TropeKevin has been writing professionally since 2015. As one who&039;s watched anime since childhood, he has great familiarity with the industry.
Read more »
New Type of Reversible Male Contraception Proves a Success in Mouse StudyThe Best in Science News and Amazing Breakthroughs
Read more »
Discovery’s Finale Proves 5 Star Trek Seasons Is Not The New 7Mark Donaldson is a writer, podcaster, and film programmer specializing in Star Trek and Doctor Who.
Read more »
New JoJo's Bizarre Adventure Cosplay Proves How Stone Ocean Could Work in Live ActionErmes Costello and her Stand Kiss in JoJo&39;s Bizarre Adventure
Read more »
Star Wars' Incredible New Jedi Master Proves The Sith Code Is TrueJedi Master Sol with his lightsaber ignited in Star Wars The Acolyte.
Read more »